

## SYNVISC<sup>®</sup>/Synvisc-One<sup>®</sup> has properties to closely match healthy, young synovial fluid<sup>1-3\*</sup>

### Elasticity and viscosity\*

	Elasticity (Pa at 2.5 Hz)	Viscosity (Pa at 2.5 Hz)
Healthy, young synovial fluid <sup>1,2†</sup>	117	45
SYNVISC <sup>®</sup> /Synvisc-One <sup>®1,2</sup>	111	25

### Molecular weight of viscosupplements\*

	Molecular weight (million Daltons)
Healthy, young synovial fluid <sup>3‡</sup>	6
SYNVISC <sup>®</sup> /Synvisc-One <sup>®1,2</sup>	6
Joint disease synovial fluid <sup>4§</sup>	1.1–1.9
Durolane <sup>®</sup>	n/a
Monovisc <sup>™5</sup>	1.0–2.9
Cingal <sup>®5,6</sup>	1.0–2.9
NeoVisc <sup>®7</sup>	1.5
Orthovisc <sup>®8</sup>	1.0–2.9

n/a=not applicable.

\* Values may be approximations and not exact figures. Comparative clinical significance is unknown.


† As in 18- to 27-year-olds.

‡ As in 21- to 45-year-olds.

§ Synovial fluids from the knees of patients with degenerative joint disease (n=29), osteoarthritis (n=16), diabetic arthropathy (n=12), gout (n=7) and acute inflammatory joint disease (n=7) were investigated. The median value of the weight-average molecular weight of hyaluronan in synovial fluids varied between 1.09 X 10<sup>6</sup> g/mol (acute-inflammatory joint disease) and 1.91 X 10<sup>6</sup> g/mol (degenerative joint disease).

# SYNVISC®/Synvisc-One® has a high molecular weight to closely mimic healthy, young synovial fluid<sup>1-3\*</sup>

## Molecular weight of viscosupplements<sup>1-8\*</sup>



Adapted from SYNVISIC® Instructions for use, Synvisc-One® Instructions for Use, Balazs EA, et al., Praest BM, et al., Monovisc Instructions for Use, NeoVisc® data on file, and Orthovisc® Prescribing Information.

\* Values may be approximations and not exact figures. Comparative clinical significance is unknown.

† Synovial fluids from the knees of patients with degenerative joint disease (n=29), osteoarthritis (n=16), diabetic arthropathy (n=12), gout (n=7) and acute inflammatory joint disease (n=7) were investigated. The median value of the weight-average molecular weight of hyaluronan in synovial fluids varied between 1.09 X 10<sup>6</sup> g/mol (acute-inflammatory joint disease) and 1.91 X 10<sup>6</sup> g/mol (degenerative joint disease).

### Important Treatment Considerations

**SYNVISC®** (hylan G-F 20) is an intra-articular injection used to treat pain associated with osteoarthritis of the knee, hip, ankle and shoulder. SYNVISIC® contains small amounts of avian protein and should not be used in patients with related hypersensitivities. Adverse events involving the injected joint after intra-articular injections of SYNVISIC® may include transient pain and/or swelling and/or effusion. Cases of acute inflammation, characterized by joint pain, swelling, effusion and sometimes joint warmth and/or stiffness, have been reported following an intra-articular injection of SYNVISIC®. Hypersensitivity reactions including anaphylactic reaction, anaphylactoid reaction, anaphylactic shock and angioedema have been reported. The post-marketing experience has identified the following systemic events to occur rarely with SYNVISIC® administration: rash, hives, itching, fever, nausea, headache, dizziness, chills, muscle cramps, paresthesia, peripheral edema, malaise, respiratory difficulties, flushing, and facial swelling. If venous or lymphatic stasis is present, SYNVISIC® should not be injected into the joint. SYNVISIC® should not be used in infected or inflamed joints or in patients having skin diseases or infections in the area of the injection site. SYNVISIC® should not be injected intravascularly, extra-articularly, or into the synovial tissues and capsule. Do not concomitantly use disinfectants containing quaternary ammonium salts for skin preparation because hyaluronan can precipitate in their presence. Some cases of skin necrosis have been reported after intra-articular use of hyaluronic acid. Patients should be instructed to contact their treating physician if signs of skin disorder (such as change of colour or open sores) appear.<sup>1</sup>

**Synvisc-One®** (hylan G-F 20) is an intra-articular injection used to treat pain associated with osteoarthritis of the knee. Synvisc-One® contains small amounts of avian protein and should not be used in patients with related hypersensitivities. Adverse events involving the injected knee after intra-articular injections of Synvisc-One® may include transient pain and/or swelling and/or effusion. Hypersensitivity reactions including anaphylactic reaction, anaphylactoid reaction, anaphylactic shock and angioedema have been reported. The post-marketing experience has identified the following systemic events to occur rarely with SYNVISIC® administration: rash, hives, itching, fever, nausea, headache, dizziness, chills, muscle cramps, paresthesia, peripheral edema, malaise, respiratory difficulties, flushing, and facial swelling. If venous or lymphatic stasis is present, Synvisc-One® should not be injected into the knee. Synvisc-One® should not be used in infected or inflamed knees or in patients having skin diseases or infections in the area of the injection site. Synvisc-One® should not be injected intravascularly, extra-articularly, or into the synovial tissues and capsule. Do not concomitantly use disinfectants containing quaternary ammonium salts for skin preparation because hyaluronan can precipitate in their presence. Some cases of skin necrosis have been reported after intra-articular use of hyaluronic acid. Patients should be instructed to contact their treating physician if signs of skin disorder (such as change of colour or open sores) appear.<sup>2</sup>

References: 1. SYNVISIC® Instructions for Use, Genzyme Canada Inc., June 10, 2023. 2. Synvisc-One® Instructions for Use, Genzyme Canada Inc., June 9, 2023. 3. Balazs EA, Watson D, Duff IF and Roseman S. Hyaluronic acid in synovial fluid. I: molecular parameters of hyaluronic acid in normal and arthritic human fluids. *Arthritis Rheum* 1967;10(4):357-76. 4. Praest BM, Greiling H and Kock R. Assay of synovial fluid parameters: hyaluronan concentration as a potential marker for joint diseases. *Clin Chim Acta* 1997;266(2):117-28. 5. Monovisc™ Instructions for Use. Anika Therapeutics, Inc. July 2020. 6. Cingal® Product Information. Anika Therapeutics, Inc. December 2015. 7. NeoVisc® Data on file. Stellar Pharmaceuticals. Inc. Oct. 13, 2005. 8. Orthovisc® Prescribing Information, DePuy Mitek, Inc. June 2005.

SYNVISC® and Synvisc-One® are registered trademarks of Genzyme Corporation.

All trademarks are the property of their respective owner(s).

© 2023 sanofi-aventis Canada Inc. All rights reserved.

MAT-CA-2000920-V3. 06/2023